GLP-1 drugs linked to temporary hair loss: Here's why

• The use of GLP-1s, such as Ozempic and Wegovy, may increase the risk of hair loss, a new study has found.
• Non-scarring alopecia, a typically nonpermanent type of hair loss, was more common among GLP-1 users than among those who took SGLT-2 inhibitors or DPP-4 inhibitors for the treatment of type 2 diabetes.
• While the absolute risk of hair loss may be low, raising awareness can help people make informed decisions about their treatment plan.

A new large-scale study found that people with type 2 diabetes who are taking GLP-1 medications may have a higher risk of hair loss.

The research, published in The BMJ, compared the risk of alopecia, a form of hair loss, among adults who took either GLP-1 drugs, SGLT-2 inhibitors, or DPP-4 inhibitors for the treatment of diabetes.

Specifically, there was an increased risk of non-scarring alopecia, a typically temporary or reversible type of hair loss, which can include telogen effluvium and androgenetic alopecia.

While the researchers suggest that the absolute risk of hair loss with GLP-1 medications is low, understanding the potential for alopecia may help inform treatment decisions among patients.